Ketamine for Depression and Alcohol Dependence

Conditions

Alcohol Dependence | Depression

What is the purpose of this trial?

The purpose of this study is to evaluate the efficacy of ketamine in reducing depressive symptoms in subjects with a comorbid major depressive episode and alcohol dependence. The investigators hypothesize the following for the present study:

A single dose of ketamine will induce a rapid, robust and sustained reduction in depressive symptoms in subjects with a comorbid major depressive episode and alcohol dependence relative to placebo as defined by change in Hamilton Depression Rating Scale total scores at 72 hours post infusion.

A single dose of ketamine can be delivered safely, with minimal adverse events or complications, in subjects with a comorbid major depressive episode and alcohol dependence.



Participation Guidelines

Age:
21 Years - 65 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
VA Connecticut Healthcare System
Yale University
Dates:
March 2012
Last Updated:
April 24, 2012
Study HIC#:
1111009339

Clinicaltrials.gov ID: NCT01551329